American Vanguard (AVD) 8-K American Vanguard Reports Second Quarter & Mid-year 2015 Results

Exhibit 99.1

FOR IMMEDIATE RELEASE

AMERICAN VANGUARD REPORTS SECOND QUARTER & MID-YEAR 2015 RESULTS

Newport Beach, CA – July 30, 2015 – American Vanguard Corporation (NYSE:AVD), today announced financial results for the second quarter and six-month period ended June 30, 2015.

Fiscal 2015 Second Quarter Financial Highlights – versus Fiscal 2014 Second Quarter Results

• Net sales declined from $68.3 million to $66.5 million

• Net income increased from $0.1 million to $0.8 million

• Earnings per diluted share increased from $0.01 to $0.03

Fiscal 2015 Six Month Financial Highlights – versus Fiscal 2014 Six Month Results

• Net sales declined from $149.4 million to $133.1 million

• Net income declined from $2.3 million to $0.8 million

• Earnings per diluted share declined from $0.08 to $0.03

Note: Further details are available in the financial schedules attached to this press release

Eric Wintemute, Chairman and CEO of American Vanguard, stated: “Our quarterly performance was mixed, with lower sales but higher net income than the comparable period last year. While sales of our insecticides declined, we saw year-over-year quarterly revenue gains in AMVAC’s herbicides, fumigants, growth regulators, toll manufacturing and International business. Further, increased manufacturing utilization, improved cost efficiency and lower operating expenses enabled us to improve our profitability.”

Mr. Wintemute continued: “I am pleased to report that during the second quarter, we acquired two product lines - Nemacur and Hyvar/Krovar - that will enhance our international business and did so without significantly increasing our debt position. We were able to accomplish this through closely managing working capital to optimize cash generation. We intend to continue this kind of fiscal control.”

Mr. Wintemute concluded: “During the second half of the year, our focus will be on multiple markets, both domestic and international, including potatoes, sugar beets, fruits and vegetables and vector control. With respect to corn, in the upcoming 2016 planting season, we look forward to commercializing our new high-concentration granular soil insecticides, further strengthening our industry-leading portfolio of granular products for prescription planting.”

Conference Call

Eric Wintemute, Chairman & CEO, David Johnson, VP & CFO, and Bob Trogele, EVP & COO of AMVAC Chemical will conduct a conference call focusing on the financial results at 4:30 pm ET / 1:30 pm PT on Thursday, July 30, 2015. Interested parties may participate in the call by dialing (201) 493-6744 - please call in 10 minutes before the call is scheduled to begin, and ask for the American Vanguard call. The conference call will also be webcast live via

theNews and Mediasection of the Company’s web site at www.american-vanguard.com. To listen to the live webcast, go to the web site at least 15 minutes early to register, download and install any necessary audio software. If you are unable to listen live, the conference call will be archived on the Company’s web site.

About American Vanguard

American Vanguard Corporation is a diversified specialty and agricultural products company that develops and markets products for crop protection and management, turf and ornamentals management and public and animal health. American Vanguard is included on the Russell 2000^® and Russell 3000^® Indexes as well as the S&P Small Cap 600 Index. To learn more about American Vanguard, please reference the Company’s web site atwww.amvac-chemical.com.

The Company, from time to time, may discuss forward-looking information. Except for the historical information contained in the conference call referenced in this release, all forward-looking statements are estimates by the Company’s management and are subject to various risks and uncertainties that may cause results to differ from management’s current expectations. Such factors include weather conditions, changes in regulatory policy and other risks as detailed from time-to-time in the Company’s SEC reports and filings. All forward-looking statements, if any, in this release represent the Company’s judgment as of the date of this release.

Company Contact:	Investor Representative
American Vanguard Corporation	The Equity Group Inc.
William A. Kuser, Director of Investor Relations	www.theequitygroup.com
(949) 260-1200	Lena Cati
williamk@amvac-chemical.com	Lcati@equityny.com (212) 836-9611

AMERICAN VANGUARD CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME

(In thousands, except per share data)

(Unaudited)

	For the three months ended June 30						For the six months ended June 30
	2015			2014			2015			2014
Net sales	$	66,523		$	68,313		$	133,088		$	149,408
Cost of sales		41,402			42,253			83,317			94,443
Gross profit		25,121			26,060			49,771			54,965
Operating expenses		23,922			25,337			48,266			50,536
Operating income		1,199			723			1,505			4,429
Interest expense		710			857			1,390			1,488
Interest capitalized		(48	)		(13	)		(87	)		(31	)
Income (loss) before provision for income taxes and loss on equity investment		537			(121	)		202			2,972
Income taxes (benefit) expense		(393	)		(160	)		(685	)		856
Income before loss on equity investment		930			39			887			2,116
Less net loss from equity method investment		(191	)		(68	)		(191	)		(140	)
Net income (loss)		739			(29	)		696			1,976
Add back net loss attributable to non-controlling interest		42			174			136			328
Net income attributable to American Vanguard		781			145			832			2,304
Change in fair value of interest rate swaps		—			145			—			281
Foreign currency translation adjustment		(323	)		92			(571	)		143
Comprehensive income	$	458		$	382		$	261		$	2,728
Earnings per common share—basic	$	.03		$	.01		$	.03		$	.08
Earnings per common share—assuming dilution	$	.03		$	.01		$	.03		$	.08
Weighted average shares outstanding—basic		28,676			28,408			28,602			28,404
Weighted average shares outstanding—assuming dilution		29,202			28,795			29,103			28,877

AMERICAN VANGUARD CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except per share data)

(Unaudited)

ASSETS

	June 30, 2015			Dec. 31, 2014
Current assets:
Cash and cash equivalents	$	5,089		$	4,885
Receivables:
Trade, net of allowance for doubtful accounts of $123 and $166, respectively		74,698			86,027
Other		4,750			2,396
Total receivables		79,448			88,423
Inventories		165,234			165,631
Prepaid expenses		13,133			13,415
Income taxes receivable		6,849			5,964
Deferred income tax assets		8,731			8,731
Total current assets		278,484			287,049
Property, plant and equipment, net		48,975			50,026
Intangible assets, net of applicable amortization		133,129			100,211
Other assets		32,415			35,035
	$	493,003		$	472,321
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Current installments of other notes payable	$	10,072		$	71
Current installments of other liabilities		2,098			1,357
Accounts payable		20,019			20,411
Deferred revenue		4,509			898
Accrued program costs		69,603			52,546
Accrued expenses and other payables		5,052			5,962
Total current liabilities		111,353			81,245
Long-term debt and other notes payable, excluding current installments		87,614			98,605
Other liabilities, excluding current installments		2,994			3,309
Deferred income tax liabilities		28,159			28,159
Total liabilities		230,120			211,318
Commitments and contingent liabilities
Stockholders’ equity:
Preferred stock, $.10 par value per share; authorized 400,000 shares; none issued		—			—
Common stock, $.10 par value per share; authorized 40,000,000 shares; issued 31,617,282 shares at June 30, 2015 and 31,550,477 shares at December 31, 2014		3,162			3,156
Additional paid-in capital		67,714			66,232
Accumulated other comprehensive loss		(2,541	)		(1,970	)
Retained earnings		202,748			202,488
		271,083			269,906
Less treasury stock, at cost, 2,450,634 shares at June 30, 2015 and December 31, 2014		(8,269	)		(8,269	)
American Vanguard Corporation stockholders’ equity		262,814			261,637
Non-controlling interest		69			(634	)
Total stockholders’ equity		262,883			261,003
	$	493,003		$	472,321

AMERICAN VANGUARD CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

For The Six Months Ended June 30, 2015 and 2014

(Unaudited)

Increase (decrease) in cash	2015			2014
Cash flows from operating activities:
Net income	$	696		$	1,976
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Depreciation and amortization of fixed and intangible assets		7,864			7,996
Amortization of other long term assets		2,734			3,027
Amortization of discounted liabilities		154			175
Stock-based compensation		2,485			1,806
Tax benefit from exercise of stock options		(7	)		(262	)
Operating loss from equity method investment		191			396
Gain from dilution of equity method investment		—			(256	)
Changes in assets and liabilities associated with operations:
Decrease (increase) in net receivables		8,975			(1,025	)
Decrease (increase) in inventories		397			(35,410	)
Decrease (increase) in prepaid expenses and other assets		143			(5,049	)
(Increase) decrease in income tax receivable/payable, net		(878	)		120
Decrease in accounts payable		(392	)		(16,521	)
Increase (decrease) in deferred revenue		3,611			(2,276	)
Increase in other payables and accrued expenses		17,851			16,264
Net cash provided by (used in) operating activities		43,824			(29,039	)
Cash flows from investing activities:
Capital expenditures		(3,480	)		(3,954	)
Investment		(125	)		—
Acquisitions of product lines and other intangibles assets		(36,435	)		—
Net cash used in investing activities		(40,040	)		(3,954	)
Cash flows from financing activities:
Net (payments) borrowings under line of credit agreement		(11,120	)		34,430
Increase in other notes payable		10,000			—
Payments on other long-term liabilities		(899	)		(1,109	)
Tax benefit from exercise of stock options		7			262
Repurchases of common stock		—			(1,531	)
Payment of cash dividends		(1,141	)		(2,836	)
Net (payments) proceeds from the issuance of common stock (sale of stock under ESPP and exercise of stock options)		(40	)		1,196
Net cash (used in) provided by financing activities		(3,193	)		30,412
Net increase (decrease) in cash and cash equivalents		591			(2,581	)
Cash and cash equivalents at beginning of period		4,885			6,680
Effect of exchange rate changes on cash		(387	)		90
Cash and cash equivalents at end of period	$	5,089		$	4,189